inCVAX

An In situ Autologous Cancer vaccine

Tomas Hode, PhD
CEO, Immunophotonics
No Access, No Hope

- 8 million cancer deaths each year internationally
- Lack of access to promising and/or proven drugs and therapies that can potentially save lives, both in low- and high-income countries:
  - >70% of cancer deaths occur in low- and middle-income countries (low incidence, high mortality)
  - 90% of patients that are out of options in high-income countries do not make it to a clinical trial (no access, or does not meet inclusion/exclusion criteria)

“400 cancer patients will die during this presentation”
inCVAX

- A local intervention that induces a broad systemic anti-tumor response
- Two injections into any one tumor
- Exposes whole-cell tumor antigens and activates antigen presenting cells, triggering a systemic tumor-specific T-cell response

- inCVAX is:
  - Practical
  - Cost Effective
  - Nontoxic
  - Effective?
International Clinical Partnerships

- Approached by investigators who desired to explore a **safe** and **practical** treatment
- Specifically for **end-stage patients** with no other available options
- Volunteers supported the program to help patients in need
- Required partners to manage regulatory environment and approvals
- **Challenges**: There were obstacles to overcome - Financial, Cultural, Basic Needs (e.g. transportation), Regulatory, etc.
Results

• These international first-in-man studies showed promising results
• Stage III and IV patients with complete responses
• Treatment is well tolerated, with minimal adverse reactions
• inCVAX can be repeated multiple times, no anamnestic immune responses
• No hospitalization: Patients could continue with normal daily activities
Case Studies: Stage IV Breast Cancer

Before Treatment

2.5 months after treatment

Before treatment

9 months after treatment

Left upper anterior chest wall

Right lower anteromedial lung

05/24/10

05/21/12
Observations

- inCVAX is safe, practical, and potentially highly effective
- Can be performed in a doctor’s office, or even out in the field
- Ideal as a combination therapy with e.g. $T_{\text{reg}}$ inhibitors and other immunotherapy
- Early access to promising new therapies can save lives internationally
- So what’s next?
I Can Win (icanwin.org) is a newly formed non-profit with the purpose to:

- Manage and expand the Early Access Program
- Identify and enroll promising and/or proven therapies that are cost effective, practical, and deemed safe enough (in the local regulatory environment) for compassionate use
- Help early stage companies and projects to collect critical data to reduce regulatory and financial risk
- Accelerate the development of potentially life-saving new technologies

www.icanwin.org
info@icanwin.org
Call for Partnership!

- We call for partnership!
  - To continue development of inCVAX in the US and internationally
  - To manage the Early Access Program and engage hospitals and clinics internationally
  - Donate expertise and time to I Can Win by joining the board of directors
  - And of course, funding support for both organizations is critical to our success
Thank You! info@immunophotonics.com